Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer.
Kirsten A NyropE M DamoneA M DealS B WheelerM CharlotB B ReeveE BaschS S ShacharL A CareyK E Reeder-HayesE C DeesT A JollyG G KimmickM S KaruturiR E ReinboltJ C SpecaW A WoodH B MussPublished in: Breast cancer research and treatment (2021)
Except for lymphedema and peripheral neuropathy, Black and White patients reported similar symptom severity during adjuvant chemotherapy. Dose reductions in Black patients were more common for non-anthracycline regimens. In this sample, there were minimal differences in patient-reported symptoms and other adverse outcomes in Black versus White patients.
Keyphrases
- patient reported
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- type diabetes
- oxidative stress
- metabolic syndrome
- depressive symptoms
- patient reported outcomes
- pregnant women
- radiation therapy
- insulin resistance
- polycystic ovary syndrome
- rectal cancer
- sleep quality